QR code

Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients

Immunotherapy in the form of ICIs has revolutionized advanced NSCLC treatment algorithms, with ICI-containing combination treatments being the latest addition to approved regimens. However, PD-L1 still represents the only routinely assessed and validated biomarker apart from genetic drivers testing,...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Luigi Della Gravara, Ciro Battiloro, Antonietta Letizia, Rosa Cantile, Vito D'Agnano, Giacomo Sica, Danilo Rocco
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: MDPI AG 2021-06-01
Reeks:Journal of Molecular Pathology
Onderwerpen:
advanced NSCLC
immunotherapy
predictive biomarkers
PD-L1
TMB
TILS
Online toegang:https://www.mdpi.com/2673-5261/2/2/17
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items